Private Advisor Group
BIB icon

Private Advisor Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Private Advisor Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,000
Closed -$212K – 2298
2023
Q2 		$212K Hold
4,000
– – ﹤0.01% 1821
2023
Q1 		$217K Hold
4,000
– – ﹤0.01% 1757
2022
Q4 		$231K Buy
+4,000
New +$225K 0.01% 844

Other funds holding BIB

Cassaday & Co Wealth Management
Cassaday & Co Wealth Management Mclean, Virginia $5.32B AUM 22.63% 1-Year Est. Return
Chase Investment Counsel
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.74B AUM 15.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Jump Financial
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return

Private Advisor Group's BIB Position: Q3 2023 in Review

Private Advisor Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2023, closing a stake of 4,000 shares — an estimated $212K sold.

Private Advisor Group first reported a position in BIB in Q4 2022 and held it in 3 quarters. The position peaked at $231K in Q4 2022. 20 funds tracked by Wall St. Rank hold BIB as of Q3 2023.

  • Private Advisor Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Private Advisor Group sold 4,000 ProShares Ultra NASDAQ Biotechnology shares in Q3 2023, an estimated $212K.
  • Private Advisor Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2022 and held it in 3 quarters.
  • Private Advisor Group's ProShares Ultra NASDAQ Biotechnology position peaked at $231K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2023.

Based on Private Advisor Group's 13F filing for Q3 2023, filed 3 Nov 2023.